Patents

Pharma company announces amino acid patent filing

Published in Obesity and Diabetes Week, January 17th, 2005

SCOLR Pharma, Inc., (AMEX: DDD - News) announced that the company has filed a provisional patent application with the U.S. Patent and Trademark Office utilizing the company's patented amino acid technology for a method to improve the oral delivery and bioavailability of Rosiglitazone.

Rosiglitazone is the active pharmaceutical ingredient used in the prescription drugs Avandia (Rosiglitazone maleate) and Avandamet (Metformin HCl/Rosiglitazone maleate) to treat type II diabetes. In 2003, GlaxoSmithKline (NYSE: GSK - News) reported nearly $1.5 billion in global Avandia and Avandamet sales.

Provisional patents allow a filer to establish a priority filing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-01-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry